Appl. No.: Unassigned Filing Date: Herewith

Amendments to the Claims:

This listing of claims will replace all prior versions, and lisitngs, of claims in the present application.

Listing of Claims:

Claims 1-35 (canceled)

Claim 36 (new) A method of expressing an HPV polypeptide in a mammalian cell comprising (a) providing a polynucleotide encoding an HPV polypeptide wherein the codon usage pattern of the of the polynucleotide resembles the codon usage pattern of highly expressed mammalian genes, and (b) delivering the polynucleotide to a mammalian cell, wherein encoded polypeptide is expressed by the mammalian cell.

Claim 37 (new) The method of Claim 36 wherein the mammalian cell is a human cell.

Claim 38 (new) The method of Claim 36 wherein the mammalian cell is a human cell

Claim 39 (new) The method of Claim 38 wherein the early protein is a member selected from the group consisting of E1, E2 and E7.

Claim 40 (new) The method of Claim 38 wherein the polypeptide comprises more than one HPV early protein.

Claim 41 (new) The method of Claim 36 wherein the HPV polypeptide is from at least one member selected from the group consisting of HPV 6a, HPV 6b, HPV 11, HPV 16, HPV 18, HPV 33 or HPV 45.

Claim 42 (new) The method of Claim 41 wherein the HPV polypeptide is from at least one member selected from the group consisting of HPV 6a, HPV6b and HPV11

Claim 43 (new) The method of Claim 42 wherein the HPV polypeptide is an E2 protein.

Appl. No.: Unassigned Filing Date: Herewith

Claim 44 (new) The method of Claim 36 wherein the codon usage pattern has a codon usage coefficient for highly expressed human genes of greater than 0.3

Claim 45 (new) The method of Claim 44 wherein the codon usage pattern has a codon usage coefficient for highly expressed human genes of greater than 0.4.

Claim 46 (new) The method of Claim 45 wherein the codon usage pattern has a codon usage coefficient for highly expressed human genes of greater than 0.5 but less than 1.

Claim 47 (new) A method for preventing or treating an HPV infection in a human, or a symptom or disease associated therewith, comprising administering to a human a polynucleotide encoding an HPV polypeptide wherein the codon usage pattern of the polynucleotide resembles the codon usage pattern of highly expressed mammalian genes.

Claim 48 (new) The method of Claim 47 wherein the polynucleotide is provided in the form of a vector.

Claim 49 (new) The method of Claim 48 wherein the vector is a plasmid.

Claim 50 (new) The method of Claim 48 wherein the vector is a viral vector.

Claim 51 (new) The method of Claim 47 wherein the polynucleotide is administered by needle injection.

Claim 52 (new) The method of Claim 47 wherein the polynucleotide is administered by particle-mediated DNA delivery.

Claim 53 (new) The method of Claim 47 wherein the polynucleotide is administered topically.